Skip to main content
. Author manuscript; available in PMC: 2009 Nov 15.
Published in final edited form as: Clin Cancer Res. 2008 Nov 15;14(22):7413–7422. doi: 10.1158/1078-0432.CCR-08-0239

Fig. 6.

Fig. 6

Noninvasive imaging assessment of response to EGFR blockade with cetuximab in HCT-116 xenograft-bearing mice. Treated and untreated cohorts bearing HCT-116 xenograft tumors were simultaneously imaged with NIR800-EGF, NIR700-Annexin V, and [18F] FLT PET. Following cetuximab treatment, NIR800-EGF uptake in HCT-116 tumors appeared modestly reduced, although the difference was not significant (A). NIR700-Annexin V uptake (B) was similar in both treated and untreated mice. C, cetuximab-treated HCT-116 mice displayed modestly reduced [18F] FLTuptake compared with untreated controls that approached statistical significance. Representative NIR800-EGF, NIR700-Annexin V, and [18F] FLT PET images were collected from an individual control (D, F, and H) and treated (E, G, and I) mouse. Strong agreement between the imaging metrics of response and standard immunohistochemistry was observed. Tumors from control (J) and treated (K) animals exhibited similar levels of total EGFR. Caspase-3 staining was similar in both control (L) and treated (M) tumors. No discernible difference in Ki-67 staining was observed between tumors from control (N) and treated (O) cohorts.